Xiaosong Wu

Xiaosong Wu

Auto-generated profile, based on publicly available information

Xiaosong Wu

Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Closed access
GYGuang Yang
Guang Yang
QZQianqiao Zhang
Qianqiao Zhang
YKYuanyuan Kong
Yuanyuan Kong
BXBingqian Xie
Bingqian Xie
MGMinjie Gao
Minjie Gao
XWXiaosong Wu
Xiaosong Wu
Fucoidan is one of the major sulfated polysaccharides isolated from brown seaweeds. In this study, we determined the anti-cancer activity of fucoidan on diffuse large B cell lymphoma (DLBCL) cells both in vitro and in vivo. Fucoidan inhibited the growth of DLBCL cells in a dose- and time-dependent manner, and fucoidan treatment provoked G0/G1 cell cycle arrest, which was accompanied by p21 up-regulation and cyclin D1, Cdk4, and Cdk6 down-regulation. Fucoidan also induced caspase-dependent cell apoptosis in DLBCL cell lines and primary DLBCL cell. In addition, fucoidan treatment caused the loss of mitochondrial membrane potential and the release of cytochrome c and apoptosis-inducing factor from the mitochondria into the cytosol. Fucoidan also potentiated the activities of carfilzomib in killing DLBCL cells. Oral administration of fucoidan effectively inhibited tumor growth in xenograft mouse models. Our findings reveal the novel function of fucoidan as an anti-DLBCL agent, which can be used in the clinical treatment of DLBCL.

20 August 2015 in Oncotarget
Verified
Journal Article
Open access
GYGuang Yang
Guang Yang
MGMinjie Gao
Minjie Gao
YZYiwen Zhang
Yiwen Zhang
YKYuanyuan Kong
Yuanyuan Kong
LGLu Gao
Lu Gao
JSJumei Shi
Jumei Shi
Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
LGLu Gao
Lu Gao
MGMinjie Gao
Minjie Gao
GYGuang Yang
Guang Yang
YTYi Tao
Yi Tao
YKYuanyuan Kong
Yuanyuan Kong
JSJumei Shi
Jumei Shi
Relapse of disease and subsequent resistance to established therapies remain as major challenges in the treatment of multiple myeloma (MM). New therapeutic options are needed for these extensively pretreated patients. To explore an optimized combinational therapy, interactions between the irreversible proteasome inhibitor carfilzomib exhibiting a well-tolerated side-effect profile and histone deacetylase inhibitor (HDACi) panobinostat (LBH589) were examined in MM cells. Coadministration of carfilzomib and LBH589 led to a synergistic inhibition of proliferation in MM cells. Further studies showed that the combined treatment synergistically increased mitochondrial injury, caspase activation, and apoptosis in MM cells. Lethality of the carfilzomib/LBH589 combination was associated with the reactive oxygen species (ROS) generation and ERK1/2 inactivation. In addition, the free radical scavenger N-acetylcysteine (NAC) could block carfilzomib and LBH589-induced oxidative stress and the subsequent apoptosis. Together, these findings argue that the strategy of combining carfilzomib and LBH589 warrants attention in MM.

1 April 2019 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Closed access
TZTing Zhang
Ting Zhang
BLBo Li
Bo Li
QFQilin Feng
Qilin Feng
Zhijian XuZhijian Xu
Zhijian Xu
CHCheng Huang
Cheng Huang
WZWeiliang Zhu
Weiliang Zhu
Multiple myeloma (MM) is a refractory malignant hematological malignancy, and many therapeutic strategies have been developed to cure patients with MM. DCZ0801 is a compound that consists of oxophenamide and pterostilbene. The role of these compounds in hematological cancers such as MM has yet to be studied. In this study, we explored the potential mechanism of DCZ0801 action, its anti-tumor activity both in vitro and in vivo on MM. This study was carried out via cell cycle proliferation assay, apoptotic analysis, western blot analysis, and examination of xenotransplantation model of tumors. The in vitro studies revealed that DCZ0801 could inhibit cell proliferation and induce apoptosis by regulating both caspase-dependent and mitogen-activated protein kinase signaling pathways, inducing S-phase arrest of the cell cycle related to downregulation of CDK2, cyclin-A2, and CDC25A protein expression. The in vivo studies showed that DCZ0801 could significantly reduce the size of the tumors in nude mice. Our results demonstrated that DCZ0801 may emerge as the new therapeutic option for the patient with MM.

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MGMinjie Gao
Minjie Gao
GYGuang Yang
Guang Yang
YKYuanyuan Kong
Yuanyuan Kong
XWXiaosong Wu
Xiaosong Wu
JSJumei Shi
Jumei Shi
Smoldering multiple myeloma (SMM) is an asymptomatic precursor stage of multiple myeloma (MM) characterized by clonal bone marrow plasma cells (BMPC) ≥ 10% and/or M protein level ≥ 30 g/L in the absence of end organ damage. It represents an intermediate stage between monoclonal gammopathy of undetermined significance (MGUS) and symptomatic MM. The risk of progression to symptomatic MM is not uniform, and several parameters have been reported to predict the risk of progression. These include the level of M protein and the percentage of BMPC, the proportion of immunophenotypically aberrant plasma cells, and the presence of immunoparesis, free light-chain (FLC) ratio, peripheral blood plasma cells (PBPC), pattern of serum M protein evolution, abnormal magnetic resonance imaging (MRI), cytogenetic abnormalities, IgA isotype, and Bence Jones proteinuria. So far treatment is still not recommended for SMM, because several trials suggested that patients with SMM do not benefit from early treatment. However, the Mateos et al. trial showed a survival benefit after early treatment with lenalidomide plus dexamethasone in patients with high-risk SMM. This trial has prompted a reevaluation of early treatment in an asymptomatic patient population.

15 August 2015
Verified
Journal Article
Closed access
MGMinjie Gao
Minjie Gao
GYGuang Yang
Guang Yang
YHYing Han
Ying Han
YKYuanyuan Kong
Yuanyuan Kong
HWHuiqun Wu
Huiqun Wu
XWXiaosong Wu
Xiaosong Wu